Fibromyalgia pathogenesis provides drug target clues by Lawson, Kim
Fibromyalgia pathogenesis provides drug target clues
LAWSON, Kim <http://orcid.org/0000-0002-5458-1897>
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/15785/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
LAWSON, Kim (2016). Fibromyalgia pathogenesis provides drug target clues. Drug 
Target Review, 3, 45-49. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
People with chronic pain experience balance shifts to an en-
hanced excitation and reduced inhibition within the CNS. The enhanced
excitability of the neurophysiology reflects altered neurotransmitter
functionality and neuroplasticity augmenting sensory processing5.
Pharmacological treatments aimed at increasing antinociceptive
neurotransmission in the CNS or lower levels of pronociceptive
excitatory neurotransmitters are required. In the cerebrospinal fluid
(CFS) of FM patients increased concentrations of substance P (two to
three-fold), endogenous opioids (three to four-fold), glutamine (two-
fold), nerve growth factor (four-fold) and brain-derived neurotrophic
factor (two to four-fold) have been observed1,6. 
In contrast, the CFS levels of 5-hydroxy indoleacetic acid (5-HIAA) –
the main metabolite of serotonin, and 3-methoxy-4-hydroxy -
phenethylene (MPHG) – the main metabolite of noradrenaline, as well
as blood levels of L-tryptophan and serotonin are lower compared with
healthy controls1,6. Thus, the changed biochemistry observed in FM
 Fibromyalgia (FM) has been described as a condition of heightened generalised sensitisation to sensory input
presenting as a complex of symptoms dominated by chronic widespread pain characterised by hyperalgesia and
allodynia. A range of co-morbidities of variable intensity, such as fatigue, sleep disturbance, cognitive impairment,
anxiety and depression, are often present (Figure 1; page 46). The prevalence of this condition, which is more
common in females than males, is reported to be 2-8% of the population and presents a major financial and social
burden to patients and healthcare systems. Neuronal excitability associated with amplified responses of the central
nervous system (CNS) to peripheral input leading to central sensitisation is believed to underlie the
pathophysiology1,2. Peripheral nociceptive generators, such as nerve pathologies, neuro-inflammation, skeletal
muscle abnormalities and ischaemia, play a role in the enhancement of the central components and the pain
experienced by FM patients3,4. 
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patients is consistent with the proposed central
neuronal excitability. The raised glutamate-
stimulating N-methyl-D-aspartic acid (NMDA)
receptors in the dorsal horn of the spinal cord
may be responsible for a wind-up phenomenon
observed in FM patients. 
Diffuse noxious inhibitory control
In healthy subjects application of intense
painful stimuli activates a whole-body
analgaesia referred to as diffuse noxious
inhibitory control (DNIC), which involves
descending opioidergic and serotonergic-
noradrenergic efferent pathways from the brain
to the spinal cord that downregulate the pain
signal. In FM, compared with healthy controls,
DNIC is consistently reduced or absent7. The
altered biochemistry of serotonin and
noradrenaline in the CSF and serum is
consistent with a decreased endogenous
serotonergic and noradrenergic activity
responsible for the reduced DNIC in FM
patients. In contrast , evidence from 
FM patients indicates normal or increased
endogenous opioid activity with high baseline
occupancy of the receptors, rather than a
deficiency of endogenous opioid release6. Thus,
low-dose naltrexone (LDN), an opioid receptor antagonist, has been
proposed as an effective treatment strategy in some FM patients8.
Microglia antagonism, rather than blocking endogenous opioid release,
has been suggested as the mechanism by
which LDN reduces the severity of the FM
symptoms. Pro-inflammatory factors released
from microglia, which in FM may be abnormally
sensitised, interact with CNS neurons leading
to central facilitation of pain processing9. 
Pharmacological treatments that simul taneously raise both
serotonin and noradrenaline, for example, tricyclic antidepressants 
and serotonin noradrenaline reuptake inhibitors have gained 
interest and demonstrated efficacy in treating FM, further supporting
the involvement of the low levels of these neurotransmitters in 
the pathogenesis of the disease2. Treatment with the tricyclic
antidepressant amitriptyline also correlated the clinical response 
with normalisation of function within the bilateral thalamus and 
basal ganglia, demonstrating involvement of
serotonin and noradrenaline in several central
aspects of the pathophysiology of FM. In
contrast, drug treatments (fluoxetine, paroxe -
tine, trazodone, esreboxetine, droxidopa) that
selectively raise either of the neurotransmitter
levels, e.g., selective serotonin reuptake inhibitors and noradrenaline
reuptake inhibitors, have not demonstrated the success of the broader
spectrum interventions2. Interestingly, when amitriptyline was
administered in combination with melatonin a superior improvement in
symptoms was observed compared with amitriptyline alone10. Thus,
stimulation of melatoninergic receptors
improved the serotonergic-noradrenergic
components of the descending endogenous
pain-modulating system and, thereby, abnorm -
ality of the melatoninergic system may also
play a role in the pathogenesis of FM. 
NMDA receptor
The enhanced wind-up and central sensi -
tisation in FM has been associated with
elevated excitatory CNS neurotransmitters.
Glutamate levels in FM patients are elevated in
key pain-processing areas of the brain and
these levels change in response to successful
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Figure 1: Interrelationship of centrally- and peripherally-derived symptoms of fibromyalgia
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treatment that attenuates the pain11,12. For
example, glutamatergic activity in the insula
was decreased by pregabalin, a voltage-gated
calcium channel α2δ subunit ligand, with those
FM patients with the highest levels of
glutamate before treatment being the most
likely to respond to the drug13. Calcium ions
enable neurotransmitters to bind to vesicles at
the presynaptic membrane terminal, thus
inhibiting the α2δ subunit, and results in
decreased calcium influx and a reduction in the
release of neurotransmitters that transmit
nociceptive signals between neurons. 
In addition, a subset of FM patients
responded to NMDA receptor antagonists
(ketamine, dextromethorphan and memantine)
which would be consistent with suppression of
an increased glutamatergic activity, however
such treatments are often not well tolerated
and have limited use in the clinic2,6. Improved understanding of the
contribution of the activity of NMDA receptor subtypes in pain – and 
the other symptoms of FM – and recent development of subtype-
specific modulators should address those
limitations of this therapeutic approach14. In
addition to reducing pain, the α2δ subunit
ligands pregabalin and gabapentin have 
been reported to improve other symptoms
characteristic of FM, such as sleep, anxiety and fatigue, supporting the
involve ment of the neurotransmitter imbalances (e.g., glutamate)
targeted by these drugs in the co-morbid symptoms15. 
Identification of subtypes of the α2δ subunits, α2δ-1 and α2δ-2,
have shown that analgaesic effects are primarily due to ligands binding
to the former, whereas binding to the latter subtype appears to
contribute to CNS side effects16. Evaluation of the preferentially α2δ-1
subunit selective ligand mirogabalin (DS5565) demonstrated a
preferable efficacy profile in a treatment study
of diabetic peripheral neuropathic pain17. These
findings support testing of mirogabalin in
clinical trials with FM patients, where clinically
meaningful differences in efficacy and safety
may provide a more successful therapeutic option. 
Although efficacy is observed with modulation of bioamines or the
α2δ ligands in the management of FM symptoms, the outcomes are
often limited with a partial reduction of symptoms only in a proportion
of patients. Thus, the potential of greater benefit or more preferable
outcomes from combined therapies targeting
multiple pharmacological mechanisms has
been considered. In a single-blind randomised
trial, the combined use of pregabalin plus
paroxetine, amitriptyline or venlafaxine
resulted in significantly lower somatic symptom
and depression scale scores; better life
satisfaction; mood and sleep quality; higher
medication tolerability and less frequent
adverse effects in patients with FM18.
Suppression of neuronal excitability and
neurotransmitter release appears to be a key
pharmacological property to the management
of FM as observed with the α2δ ligands and the
bioamine modulators. Thus, anticonvulsant
drugs such as levetriactem, topiramate and
lacosamide, which suppress neuronal hyper -
excitability by a mechanism other than α2δ
subunits have been evaluated as a potential
treatment approach, but have failed to provide
sufficient evidence of efficacy against the
symptoms of FM19. The mechanism(s) of 
action of the gabapentanoids, pregabalin and
CNS
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Pharmacological treatments 
that simultaneously raise both 
serotonin have gained interest and
demonstrated efficacy 
Figure 2: Central and peripheral mechanisms related to the pathophysiology of fibromyalgia
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sensitisation in FM has been associated with
raised excitatory neurotransmitters
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gabapentin appear to provide a unique, albeit limited, control of the
neuronal hyperexcitability and central sensitisation associated with FM.
Although raised substance P levels have been reported in 
FM patients, substance P antagonists have provided inconsistent
outcomes or failed in clinical trials in FM and
other chronic pain states2,6, casting questions
about how critical this neurotransmitter is as a
drug target in pain transmission. Interestingly,
topically applied capsaicin significantly
improved the symptoms of FM20. Capsaicin binds to the transient
receptor potential vanilloid 1 subunits (TRPV1) located in peripheral
nociceptors and desensitises nociceptive processes, possibly due to
depletion of substance P21. These findings infer, at least, a peripheral
role of substance P in the regulation of peripheral generators and
sensory factors activating central neuronal mechanisms responsible for
the symptoms of FM. 
Dopamine deficiency and endocannabinoid deficiency in the CNS,
where there is an involvement in regulation of pain processing and
chronic stress, have also been implicated in the
pathophysiology of FM22,23. In patients with FM
dopamine release into the basal ganglia in
response to painful stimuli is attenuated or
absent22. Attempts to rectify this dysfunction
with dopamine receptor agonists have been inconsistent with
pramipexole improving symptoms but similar outcomes have not been
observed with ropinirole and terguride24-26. Evaluation of cannabinoids,
such as nabilone and dronabinol, as a treatment approach
demonstrated in clinical trials an improvement of quality of life in
patients with FM, but with limiting adverse
effects2. Psychotropic effects due to hepatic
metabolites from first-pass metabolism could
limit the clinical utility of cannabinoids, 
which has led to the evaluation of a trans -
dermal application of the D-(-)-glyceric acid
ester of delta-9-tetrahydrocannabinol, ZYN001
in FM patients27. 
Systemic stress-related effects associated
with alterations in the hypothalamic pituitary
adrenal axis, and autonomic and cardiovascular
system have also been suggested to enhance or
underlie the symptoms, particularly the pain, of
FM2,6. Although studies in FM generally have
shown alterations of these stress systems, the
findings of the studies are often inconsistent
with abnormal HPA or autonomic function in
only a small percentage of patients, with
significant overlap between patients and
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Figure 3: Current and emerging drug targets for treatments of fibromyalgia
The diversity of pharmacological
targets gaining interest emphasises 
the complexity of FM 
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Cannabinoids such as nabilone and
dronabinol improved quality of life in
FM patients in clinical trials
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healthy subjects. Further data also suggests that HPA and autonomic
abnormalities occur as a consequence of the pain in FM patients28.
Although inflammation has also been suggested to underlie 
the pathology in FM, literature on cytokines has been variable and the
studies have several limitations that could influence the findings1,2,6.
Pro-inflammatory cytokines might play a role in the generation and
enhancement of the chronic pain characteristic of FM, however
evidence does not as yet allow conclusions to be drawn as to whether
the inflammatory response is the cause of the symptoms or due to the
changed physiology initiating the pain. It is important to note that anti-
inflammatory drugs such as non-steroidal anti-inflammatory drugs and
steroids have been shown in clinical trials to have no or very limited
efficacy in the treatment of FM2,6. 
Conclusion
Advances in the understanding of the pathophysiology of FM are
providing clues as to underlying mechanisms as targets for new
medications (Figure 2; page 47). The alteration of multiple systems 
and biological mechanisms, both at central and peripheral levels, 
has often introduced confusion as to which processes are a cause or
consequence of FM. Bioamine modulation and voltage-gated 
Ca2+ channel α2δ subunits in addition to dopamine receptors, NMDA
receptors, cannabinoid receptors and melatonin receptors are
emerging as drug targets (Figure 3; page 48). However, the inconsistency
of clinical data for drugs that target single mechanisms support 
the requirement of therapies that modulate more than one dys -
functional neurotransmitter. 
The diversity of pharmacological targets gaining interest emphasises
the complexity of FM, but insight into potential drug treatment profiles
offers important clues for condition-focused therapies and improved
diagnosis. Further evidence of the symptoms indicates heterogeneity
with multiple potential aetiologies. Such an interpretation is consist-
ent with an heterogeneity of drug treatment outcomes often leading to
the requirement of individualised management. Finally, greater
understanding of the central and peripheral contributions to the
pathophysiology is required so that therapies can be targeted toward
both components to manage the characteristic symptoms, but also to
consider accompanying co-morbid conditions.
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